Kintara Therapeutics Set to Join Russell Microcap® Index
Kintara Therapeutics (Nasdaq: KTRA) announced its addition to the Russell Microcap Index, effective June 28, 2021. This milestone is expected to enhance investor exposure to Kintara's mission of developing innovative cancer therapies. The company is advancing its lead product, VAL-083, in the GBM AGILE study for glioblastoma. Inclusion in the Russell Microcap Index provides automatic membership in growth and value style indexes, crucial as over $10.6 trillion in assets benchmark against Russell's U.S. indexes.
- Inclusion in the Russell Microcap Index may enhance investor exposure.
- Kintara's lead product, VAL-083, is in a pivotal study, indicating ongoing clinical development.
- Kintara faces risks and uncertainties related to COVID-19 and its impact on clinical trials.
- Dependence on substantial funding for ongoing operations and product commercialization.
SAN DIEGO, June 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced Kintara's addition to the Russell MicrocapÒ Index. This milestone will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021 according to a preliminary list of additions posted June 4, 2021.
"We are delighted for Kintara to have been added to the FTSE Russell Microcap® Index, which will help increase investor exposure to our Company's mission of developing novel cancer therapies for patients with unmet medical needs," said Saiid Zarrabian, CEO of Kintara. "We look forward to the opportunity to expand awareness of our late-stage oncology pipeline of which our lead product, VAL-083, is currently being tested in GCAR's GBM AGILE registrational study for all three GBM patient subtypes of newly-diagnosed methylated MGMT, newly-diagnosed unmethylated MGMT, and recurrent GBM."
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell Indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
ABOUT KINTARA
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2020, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS:
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/kintara-therapeutics-set-to-join-russell-microcap-index-301306592.html
SOURCE Kintara Therapeutics
FAQ
What is Kintara Therapeutics' stock symbol?
When will Kintara be added to the Russell Microcap Index?
What is the significance of joining the Russell Microcap Index for Kintara?
What is Kintara's lead product currently being developed?
What are the potential risks mentioned in Kintara's press release?
